Clinical Development & Operations
Medical Director, Clinical Development, Obesity
Serve as medical lead for a Phase 2 study of an oral incretin-based therapy. You will shape the protocol, monitor safety and help plan the path into Phase 3.
A typical mandate
The company develops oral small molecules targeting incretin pathways for obesity and related metabolic disease. Its lead compound has completed Phase 1 and is entering a dose-ranging Phase 2. The medical team is small, so this role carries real ownership of the study.
What the role owns
- Act as medical monitor and clinical lead for the Phase 2 dose-ranging study
- Write and refine protocols, investigator brochures and clinical study reports
- Review safety data with drug safety, including gastrointestinal tolerability and cardiovascular signals
- Contribute to dose selection and Phase 3 design with biostatistics and regulatory
- Build relationships with endocrinology and obesity medicine investigators
- Support FDA meeting preparation and briefing documents
What great candidates bring
- MD or DO, with training in endocrinology, cardiology or internal medicine
- 4+ years in industry clinical development, including medical monitoring
- Experience with Phase 2 or Phase 3 studies in metabolic or cardiovascular disease
- Sound clinical judgment on safety signals and benefit-risk
- Familiarity with FDA guidance on developing drugs for weight reduction
- Clear writing and a steady presence with investigators
Why it matters
- Reports to the Vice President, Clinical Development
- Equity at Series C
- Real ownership of a lead program at an important stage
- Hybrid schedule
Related profiles